Therapeutic options for postmenopausal female sexual dysfunction

被引:51
作者
Al-Azzawi, F. [1 ]
Bitzer, J. [2 ]
Brandenburg, U. [3 ]
Castelo-Branco, C. [4 ]
Graziottin, A. [5 ]
Kenemans, P. [6 ]
Lachowsky, M. [7 ]
Mimoun, S. [8 ]
Nappi, R. E. [9 ]
Palacios, S. [11 ]
Schwenkhagen, A. [10 ]
Studd, J. [12 ]
Wylie, K. [13 ]
Zahradnik, H. -P. [14 ]
机构
[1] Univ Hosp Leicester, Gynaecol Res Unit, Leicester, Leics, England
[2] Univ Basel Hosp, Dept Obstet & Gynecol, CH-4031 Basel, Switzerland
[3] Klin Psychiat & Psychotherapie, Aachen, Germany
[4] Univ Barcelona, Fac Med, Inst Clin Gynecol Obstet & Neonatol, Hosp Clin,IDIBAPS, Barcelona 7, Spain
[5] H San Raffaele Resnati, Ctr Gynecol & Med Sexol, Milan, Italy
[6] Free Univ Amsterdam, Med Ctr, Dept Obstet & Gynecol, Amsterdam, Netherlands
[7] Hop Xavier Bichat, Paris, France
[8] Robert Debre Hosp, Dept Obstet & Gynecol, Unit Psychosomat Gynecol, Paris, France
[9] Univ Pavia, IRCCS Maugeri Fdn, Res Ctr Reprod Med, I-27100 Pavia, Italy
[10] Ctr Gynecol Endocrinol & Reprod Med, Hamburg, Germany
[11] Inst Palacios Salud & Med Mujer, Madrid, Spain
[12] London PMS & Menopause Ctr, London, England
[13] Porterbrook Clin, Sheffield, S Yorkshire, England
[14] Univ Frauenklin, Klin Endokrinol & Reprod Med, Freiburg, Germany
关键词
FEMALE SEXUAL DYSFUNCTION; MENOPAUSE; ESTROGEN; TESTOSTERONE; DEFICIENCY; PSYCHOSOCIAL; SURGICALLY MENOPAUSAL WOMEN; QUALITY-OF-LIFE; DESIRE DISORDER; AROUSAL DISORDER; DOUBLE-BLIND; TESTOSTERONE PATCH; DEHYDROEPIANDROSTERONE REPLACEMENT; ESTROGEN THERAPY; UNITED-STATES; PREVALENCE;
D O I
10.3109/13697130903437615
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To review the pharmacological and non-pharmacological therapies available for postmenopausal FSD, focusing on practical recommendations for managing postmenopausal women with sexual complaints, through a literature review of the most relevant publications in this field. Psychosocial therapy This type of therapy (basic counselling, physiotherapy and psychosexual intervention) is considered an adaptable step-by-step approach for diagnostic and therapeutic strategies, normally combined with biomedical interventions to provide optimal outcomes. Pharmacological therapy For postmenopausal FSD, many interventional options are now available, including hormonal therapies such as estrogens, testosterone, combined estrogen/testosterone, tibolone and dehydroepiandrosterone. Conclusions Menopause and its transition represent significant risk factors for the development of sexual dysfunction. FSD impacts greatly on a patient's quality of life. Consequently, it is receiving more attention thanks to the development of effective treatments. Non-pharmacological approaches should be used first, focusing on lifestyle and psychosexual therapy. If required, proven effective hormonal and non-hormonal therapeutic options are available.
引用
收藏
页码:103 / 120
页数:18
相关论文
共 50 条
  • [31] Female sexual dysfunction (FSD): Prevalence and impact on quality of life (QoL)
    Nappi, Rossella E.
    Cucinella, Laura
    Martella, Silvia
    Rossi, Margherita
    Tiranini, Lara
    Martini, Ellis
    MATURITAS, 2016, 94 : 87 - 91
  • [32] A systematic review of randomized controlled trials investigating the efficacy and safety of testosterone therapy for female sexual dysfunction in postmenopausal women
    Jayasena, Channa N.
    Alkaabi, Fatima M.
    Liebers, Curtis S.
    Handley, Thomas
    Franks, Stephen
    Dhillo, Waljit S.
    CLINICAL ENDOCRINOLOGY, 2019, 90 (03) : 391 - 414
  • [33] Arterial hypertension and female sexual dysfunction in postmenopausal women
    De Franciscis, P.
    Mainini, G.
    Messalli, E. M.
    Trotta, C.
    Luisi, A.
    Laudando, E.
    Marino, G.
    Della Puca, G.
    Cerreto, F. V.
    Torella, M.
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2013, 40 (01) : 58 - 60
  • [34] FLIBANSERIN FOR FEMALE SEXUAL DYSFUNCTION
    Reviriego, C.
    DRUGS OF TODAY, 2014, 50 (08) : 549 - 556
  • [35] Treatment of female sexual dysfunction
    Ragucci, KR
    Culhane, NS
    ANNALS OF PHARMACOTHERAPY, 2003, 37 (04) : 546 - 555
  • [36] Androgens and Female Sexual Function and Dysfunction-Findings From the Fourth International Consultation of Sexual Medicine
    Davis, Susan R.
    Worsley, Roisin
    Miller, Karen K.
    Parish, Sharon J.
    Santoro, Nanette
    JOURNAL OF SEXUAL MEDICINE, 2016, 13 (02) : 168 - 178
  • [37] Potential future options in the pharmacotherapy of female sexual dysfunction
    Ueckert, Stefan
    Mayer, Margit E.
    Jonas, Udo
    Stief, Christian G.
    WORLD JOURNAL OF UROLOGY, 2006, 24 (06) : 630 - 638
  • [38] Potential future options in the pharmacotherapy of female sexual dysfunction
    Stefan Ückert
    Margit E. Mayer
    Udo Jonas
    Christian G. Stief
    World Journal of Urology, 2006, 24 : 630 - 638
  • [39] Female Sexual Dysfunction: A Systematic Review of Outcomes Across Various Treatment Modalities
    Weinberger, James M.
    Houman, Justin
    Caron, Ashley T.
    Anger, Jennifer
    SEXUAL MEDICINE REVIEWS, 2019, 7 (02) : 223 - 250
  • [40] Physicians' attitudes towards androgen replacement therapy for male and female sexual dysfunction
    Lowenstein, L.
    Shechter, A.
    Porst, H.
    Tripodi, F.
    Reisman, Y.
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2016, 28 (02) : 57 - 61